open access

Vol 20, No 1 (2013)
Original articles
Published online: 2013-02-07
Get Citation

Exendin-4 attenuates ischemia-induced ventricular arrhythmias in rats

Zhang Kai, Wu Yongbo, Zhao Lin, Guo Jie, Jin Daoqun, Chen Zhiqiang
DOI: 10.5603/CJ.2013.0006
·
Cardiol J 2013;20(1):29-33.

open access

Vol 20, No 1 (2013)
Original articles
Published online: 2013-02-07

Abstract


Background: Glucagon-like peptide-1 and its receptor agonist-exendin-4 (Ex-4) have been shown to provide beneficial effects for cardiovascular diseases. This study investigated the effects of Ex-4 on ischemia-induced ventricular arrhythmias in rats.
Methods: Anesthetized male rats were once treated with Ex-4 (5 μg/kg, i.v.) 1 h before ischemia in the absence and/or presence of 5-hydroxydecanoic acid (5-HD, 10 mg/kg, i.v., a specific inhibitor of mitochondrial ATP-sensitive potassium [KATP] channels) which were once injected 10 min before ischemia. And then subjected to ischemia for 30 min. Ventricular arrhythmias were assessed.
Results: During the 30-min ischemia, Ex-4 significantly reduced the incidence of ventricular fibrillation (VF) (p < 0.05). The duration of ventricular tachycardia (VT) + VF, the number of VT + VF episodes and the severity of arrhythmias were all significantly reduced by Ex-4 compared to those in myocardial ischemia group (p < 0.05 for all). Administration of 5-HD abolished the protective effects of Ex-4 on VF incidence, the duration of VT + VF, the number of VT + VF episodes and the severity of arrhythmias (p < 0.05 for all).
Conclusions: This study suggested that Ex-4 could attenuate ischemia-induced ventricular arrhythmias in rats in which mitochondrial KATP channels may be involved.

Abstract


Background: Glucagon-like peptide-1 and its receptor agonist-exendin-4 (Ex-4) have been shown to provide beneficial effects for cardiovascular diseases. This study investigated the effects of Ex-4 on ischemia-induced ventricular arrhythmias in rats.
Methods: Anesthetized male rats were once treated with Ex-4 (5 μg/kg, i.v.) 1 h before ischemia in the absence and/or presence of 5-hydroxydecanoic acid (5-HD, 10 mg/kg, i.v., a specific inhibitor of mitochondrial ATP-sensitive potassium [KATP] channels) which were once injected 10 min before ischemia. And then subjected to ischemia for 30 min. Ventricular arrhythmias were assessed.
Results: During the 30-min ischemia, Ex-4 significantly reduced the incidence of ventricular fibrillation (VF) (p < 0.05). The duration of ventricular tachycardia (VT) + VF, the number of VT + VF episodes and the severity of arrhythmias were all significantly reduced by Ex-4 compared to those in myocardial ischemia group (p < 0.05 for all). Administration of 5-HD abolished the protective effects of Ex-4 on VF incidence, the duration of VT + VF, the number of VT + VF episodes and the severity of arrhythmias (p < 0.05 for all).
Conclusions: This study suggested that Ex-4 could attenuate ischemia-induced ventricular arrhythmias in rats in which mitochondrial KATP channels may be involved.
Get Citation

Keywords

exendin-4; ventricular arrhythmias; myocardial ischemia; mitochondrial ATP-sensitive potassium

About this article
Title

Exendin-4 attenuates ischemia-induced ventricular arrhythmias in rats

Journal

Cardiology Journal

Issue

Vol 20, No 1 (2013)

Pages

29-33

Published online

2013-02-07

DOI

10.5603/CJ.2013.0006

Bibliographic record

Cardiol J 2013;20(1):29-33.

Keywords

exendin-4
ventricular arrhythmias
myocardial ischemia
mitochondrial ATP-sensitive potassium

Authors

Zhang Kai
Wu Yongbo
Zhao Lin
Guo Jie
Jin Daoqun
Chen Zhiqiang

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl